\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Digital, Industry & Space Digital Europe AI ContinentThe European Commission has published a document to respond to Frequently Asked Questions (FAQs) on the Data Act.
The Data Act, which will become applicable on 12 September 2025, establishes a horizontal set of rules on data access and use that aims to protect fundamental rights and to deliver wide-ranging benefits for the European economy and society. It increases data availability – particularly industrial data – and encourages data-driven innovation while ensuring fairness in the allocation of data value among all actors in the data economy.
It will contribute to the establishment of a single market for data, together with the Data Governance Act, which aims to increase trust in voluntary data-sharing mechanisms.
As applicants to data-related call topics are expected to be aware of relevant EU policies and legislation, these FAQs can provide a useful overview on the Data Act.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
AI Continent Deployment: Best use of technologies
The European Commission has published the recording and presentations from its 18 December 2025 info session on the call topics Data Space for Manufacturing (DIGITAL-2026-DSM-AI-09-DS-MANUFACTUR-STEP) and European Digital Media Observatory hubs (DIGITAL-2026-BESTUSE-TECH-EDMO-09-HUBS). The slides and recording are available on ... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
